Impact of Age on Outcomes with Immunotherapy in Patients with Non-Small Cell Lung Cancer
Impact of Age on Outcomes with Immunotherapy in Patients with Non-Small Cell Lung Cancer
复制标题
DOI：
10.1016/j.jtho.2018.11.011
复制
发表时间：
2019-03-01
影响因子：
20.4
通讯作者：
Gainor, Justin F.
中科院分区：
文献类型：
--
作者：
Lichtenstein, Morgan R. L.;Nipp, Ryan D.;Gainor, Justin F.
简介：免疫疗法彻底改变了非小细胞肺癌的治疗，但很少有人知道的活动，程序性细胞死亡1和程序性死亡配体1封锁跨年龄groups.Methods：我们回顾性评估了非小细胞肺癌患者谁启动程序性细胞死亡1和程序性死亡配体1抑制剂从2013年1月至2017年7月。对病历和放射学影像进行审查，以确定无进展生存期（PFS）和总生存期（OS）。我们还比较了免疫治疗相关的毒性，类固醇的使用，和住院年龄。结果：在245例患者中，26.1%的年龄小于60岁，31.4%的年龄为60至69岁，31.0%的年龄为70至79岁，11.4%的年龄为80岁或以上。按年龄组列出的中位PFS时间如下：60岁以下，1.81个月; 60 - 69岁，2.53个月; 70 - 79岁，3.75个月; 80岁或以上，1.64个月（对数秩p值= 0.055）。按年龄组列出的中位OS时间如下：60岁以下，13.01个月; 60 - 69岁，14.56个月; 70 - 79岁，12.92个月; 80岁或以上，3.62个月（对数秩p值= 0.011）。免疫治疗相关的毒性反应，类固醇的使用和住院率并没有显着差异的年龄。结论：虽然免疫治疗的OS和PFS的好处不同的年龄，无论年龄的毒性率是相似的。(C)2018年国际肺癌研究协会。爱思唯尔公司出版All rights reserved.
Introduction: Immunotherapy has revolutionized the treatment of NSCLC, but little is known about the activity of programmed cell death 1 and programmed death ligand 1 blockade across age groups.Methods: We retrospectively evaluated patients with NSCLC who initiated programmed cell death 1 and programmed death ligand 1 inhibitors from January 2013 through July 2017. Medical records and radiographic imaging were reviewed to determine progression-free survival (PFS) and overall survival (OS). We also compared immunotherapy-related toxicities, steroid use, and hospitalizations by age.Results: Of the 245 patients, 26.1% were younger than 60 years, 31.4% were age 60 to 69 years, 31.0% were age 70 to 79 years, and 11.4% were age 80 years or older. The median PFS times by age group were as follows: younger than 60 years, 1.81 months; age 60 to 69 years, 2.53 months; age 70 to 79 years, 3.75 months; and age 80 years or older, 1.64 months (log-rank p value = 0.055). The median OS times by age group were as follows: younger than 60 years, 13.01 months; age 60 to 69 years, 14.56 months; age 70 to 79 years, 12.92 months; and age 80 years or older, 3.62 months (log-rank p value = 0.011). Rates of immunotherapy-related toxicities, steroid use, and hospitalizations did not differ by age.Conclusions: Although the OS and PFS benefits of immunotherapy differ by age, the rates of toxicity are similar regardless of age. (C) 2018 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.